** CSL CSL.AX up 2.7% at A$199.5, set for strongest trading session since July 22

** Biotech major tracks gains on ASX Healthcare sub-index .AXHJ, which is up 1.9%

** UBS estimates $1.2 bln unmitigated EBIT hit from Trump's 100% tariffs on patented drugs

** Broker sees potential company-wide tariff exemption tied to accelerating U.S. fractionation facility with investment of $1.5-2 bln

** Expects limited scope to offset costs via higher U.S. drug pricing, more likely alternative is redirection of co's Behring and Seqirus sales outside the U.S. but at lower pricing

** Sales redirection option to reduce CSL's tariff EBIT impact to $700 mln

** Brokerage rates stock "buy", PT A$300

** CSL down 29.2% YTD, including day's moves

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))